Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

EVANSVILLE, Ind. (WFIE) - At the end of July, Lilly King officially wrapped up her swimming career, racing her final meet at ...

The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United ...

Rigel's Q2 results highlight soaring revenue and raised guidance for 2025. See more on RIGL stock's growth potential, ...

Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly, accusing the drug maker of bribing doctors to prescribe ...

Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The drugmaker is one step closer to breaking ground on over 200 acres of land in a Houston development that's seeking ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of ...